<DOC>
	<DOCNO>NCT00518583</DOCNO>
	<brief_summary>The study evaluate safety efficacy combination PLD , paclitaxel , trastuzumab patient operable breast cancer . Patients treat combination 18 week , follow surgery .</brief_summary>
	<brief_title>Phase II Study Patients With Operable Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Dx clinical T1cT3 , N01 , M0 breast cancer Interval diagnosis consent &lt; 62 day Life expectancy 10 year LVEF MUGA &gt; = low limit normal test facility Negative serum pregnancy test Adequate bone marrow , renal , liver function Negative bone scan HRT discontinue study entry Adequate contraceptive method Male breast cancer Less 21 year age Ulceration , infiltration skin , complete fixation severe skin edema N3 disease node mat fixed Suspicious palpable supraclavicular node CT evidence malignant internal mammary node Pregnancy breast feed time study entry Prior therapy breast cancer Prior anthracycline malignancy Prior breast malignancy contralateral breast Prior nonbreast malignancy within 5 year Nonmalignant disease would preclude follow MI within 6 month , NYHA Class II great heart failure Psychiatric disorder condition would preclude provision inform consent</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Over-expressing Her2-neu</keyword>
</DOC>